Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI114126

Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits.

R W Mahley, K H Weisgraber, M M Hussain, B Greenman, M Fisher, T Vogel, and M Gorecki

Gladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140.

Find articles by Mahley, R. in: PubMed | Google Scholar

Gladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140.

Find articles by Weisgraber, K. in: PubMed | Google Scholar

Gladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140.

Find articles by Hussain, M. in: PubMed | Google Scholar

Gladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140.

Find articles by Greenman, B. in: PubMed | Google Scholar

Gladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140.

Find articles by Fisher, M. in: PubMed | Google Scholar

Gladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140.

Find articles by Vogel, T. in: PubMed | Google Scholar

Gladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140.

Find articles by Gorecki, M. in: PubMed | Google Scholar

Published June 1, 1989 - More info

Published in Volume 83, Issue 6 on June 1, 1989
J Clin Invest. 1989;83(6):2125–2130. https://doi.org/10.1172/JCI114126.
© 1989 The American Society for Clinical Investigation
Published June 1, 1989 - Version history
View PDF
Abstract

Plasma cholesterol levels in cholesterol-fed rabbits were markedly reduced by the intravenous infusion or bolus injection of recombinant human apo E or rabbit plasma apo E. Administration of 6-70 mg of apo E resulted in an approximately 20-40% acute reduction in plasma cholesterol levels within 2-3 h. Plasma cholesterol levels remained reduced for 4-8 h after the administration of apo E. Furthermore, the intravenous injection of apo E reduced the plasma cholesterol levels in Watanabe heritable hyperlipidemic rabbits. The addition of apo E to [14C]cholesterol-labeled canine thoracic duct lymph or [14C]cholesterol-labeled chylomicrons resulted in accelerated plasma clearance of these diet-induced lipoproteins in normal rabbits, with the uptake occurring primarily in the liver. This study suggests that the amount or availability of apo E in the plasma of cholesterol-fed rabbits may be rate limiting for the normal clearance of diet-induced remnant lipoproteins.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2125
page 2125
icon of scanned page 2126
page 2126
icon of scanned page 2127
page 2127
icon of scanned page 2128
page 2128
icon of scanned page 2129
page 2129
icon of scanned page 2130
page 2130
Version history
  • Version 1 (June 1, 1989): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts